Home > Insider Trading > Filing (0001104659-22-070156)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1175151	Cytosorbents Corp	CTSO	Surgical & Medical Instruments & Apparatus (3841)	980373793

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1442786	P. Phillip Chan	C/O Cytosorbents Corporation 7 Deer Park Drive, Suite K Monmouth Junction NJ 08852	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-06-09	16,000	$2.17	766,130	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Footnotes

Reflects open market purchases made by the reporting person on June 9, 2022. Purchase price reflects the average price of purchases made in multiple transactions at prices ranging from $2.15 to $2.18, inclusive. The reporting person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth herein upon request.
Includes (a) the following restricted stock units ("RSUs") that will be settled into shares of the Issuer's common stock upon vesting upon a "Change In Control" of the Issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;
(continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of the Issuer's common stock upon vesting: 24,000 RSUs granted on April 12, 2021 and unvested on the date hereof; and
(continued from footnote 3) (c) 526,130 shares of the Issuer's common stock owned by the reporting person, inclusive of the 16,000 shares of the Issuer's common stock reported on this Form 4.